Anand B Karnad

  • Source: Scopus
  • Calculated based on no. of publications stored in Pure and citations from Scopus
1984 …2019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Anand B Karnad is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.
  • Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

    Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., Fuereder, T., Hughes, B. G. M., Mesía, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Hong, R. L., González Mendoza, R., Roy, A., Zhang, Y. & 188 others, Gumuscu, B., Cheng, J. D., Jin, F., Rischin, D., Lerzo, G., Tatangelo, M., Varela, M., Zarba, J. J., Boyer, M., Gan, H., Gao, B., Hughes, B., Mallesara, G., Taylor, A., Burian, M., Barrios, C. H., de Castro Junior, D. O., Castro, G., Franke, F. A., Girotto, G., Lima, I. P. F., Nicolau, U. R., Pinto, G. D. J., Santos, L., Victorino, A. P., Chua, N., Couture, F., Gregg, R., Hansen, A., Hilton, J., McCarthy, J., Soulieres, D., Ascui, R., Gonzalez, P., Villanueva, L., Torregroza, M., Zambrano, A., Holeckova, P., Kral, Z., Melichar, B., Prausova, J., Vosmik, M., Andersen, M., Gyldenkerne, N., Jurgens, H., Putnik, K., Reinikainen, P., Gruenwald, V., Laban, S., Aravantinos, G., Boukovinas, I., Georgoulias, V., Kwong, D., Al-Farhat, Y., Csoszi, T., Erfan, J., Horvai, G., Landherr, L., Remenar, E., Ruzsa, A., Szota, J., Billan, S., Gluck, I., Gutfeld, O., Popovtzer, A., Benasso, M., Bui, S., Ferrari, V., Licitra, L., Nole, F., Fujii, T., Fujimoto, Y., Hanai, N., Hara, H., Matsumoto, K., Mitsugi, K., Monden, N., Nakayama, M., Okami, K., Oridate, N., Shiga, K., Shimizu, Y., Sugasawa, M., Takahashi, M., Takahashi, S., Tanaka, K., Ueda, T., Yamaguchi, H., Yamazaki, T., Yasumatsu, R., Yokota, T., Yoshizaki, T., Kudaba, I., Stara, Z., Cheah, S. K., Aguilar Ponce, J., Gonzalez Mendoza, R., Hernandez Hernandez, C., Medina Soto, F., Buter, J., Hoeben, A., Oosting, S., Suijkerbuijk, K., Bratland, A., Brydoey, M., Alvarez, R., Mas, L., Caguioa, P., Querol, J., Regala, E. E., Tamayo, M. B., Villegas, E. M., Kawecki, A., Karpenko, A., Klochikhin, A., Smolin, A., Zarubenkov, O., Goh, B. C., Cohen, G., du Toit, J., Jordaan, C., Landers, G., Ruff, P., Szpak, W., Tabane, N., Brana, I., Iglesias Docampo, L., Lavernia, J., Mesia, R., Abel, E., Muratidu, V., Nielsen, N., Cristina, V., Rothschild, S., Wang, H. M., Yang, M. H., Yeh, S. P., Yen, C. J., Soparattanapaisarn, N., Sriuranpong, V., Aksoy, S., Cicin, I., Ekenel, M., Harputluoglu, H., Ozyilkan, O., Harrington, K., Agarwala, S., Ali, H., Alter, R., Anderson, D., Bruce, J., Campbell, N., Conde, M., Deeken, J., Edenfield, W., Feldman, L., Gaughan, E., Goueli, B., Halmos, B., Hegde, U., Hunis, B., Jotte, R., Karnad, A., Khan, S., Laudi, N., Laux, D., Martincic, D., McCune, S., McGaughey, D., Misiukiewicz, K., Mulford, D., Nadler, E., Nunnink, J., Ohr, J., O'Malley, M., Patson, B., Paul, D., Popa, E., Powell, S., Redman, R., Rella, V., Rocha Lima, C., Sivapiragasam, A., Su, Y., Sukari, A., Wong, S., Yilmaz, E. & Yorio, J., Nov 23 2019, In: The Lancet. 394, 10212, p. 1915-1928 14 p.

    Research output: Contribution to journalArticlepeer-review

    200 Scopus citations
  • Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study

    Herbst, R. S., Redman, M. W., Kim, E. S., Semrad, T. J., Bazhenova, L., Masters, G., Oettel, K., Guaglianone, P., Reynolds, C., Karnad, A., Arnold, S. M., Varella-Garcia, M., Moon, J., Mack, P. C., Blanke, C. D., Hirsch, F. R., Kelly, K. & Gandara, D. R., Jan 2018, In: The Lancet Oncology. 19, 1, p. 101-114 14 p.

    Research output: Contribution to journalArticlepeer-review

    32 Scopus citations
  • Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

    Kelly, K. R., Friedberg, J. W., Park, S. I., McDonagh, K., Hayslip, J., Persky, D., Ruan, J., Puvvada, S., Rosen, P., Iyer, S. P., Stefanovic, A., Bernstein, S. H., Weitman, S., Karnad, A., Monohan, G., VanderWalde, A., Mena, R., Schmelz, M., Spier, C., Groshen, S. & 5 others, Venkatakrishnan, K., Zhou, X., Sheldon-Waniga, E., Jane Leonard, E. & Mahadevan, D., Dec 15 2018, In: Clinical Cancer Research. 24, 24, p. 6150-6159 10 p.

    Research output: Contribution to journalArticlepeer-review

    10 Scopus citations
  • The biology and role of CD44 in cancer progression: Therapeutic implications

    Chen, C., Zhao, S., Karnad, A. & Freeman, J. W., May 10 2018, In: Journal of Hematology and Oncology. 11, 1, 64.

    Research output: Contribution to journalReview articlepeer-review

    178 Scopus citations
  • Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?

    Fountzilas, C., Stuart, S., Hernandez, B., Bowhay-Carnes, E., Michalek, J. E., Sarantopoulos, J., Karnad, A. B., Patel, S., Weitman, S. D. & Mahalingam, D., Jan 19 2017, (Accepted/In press) In: Investigational New Drugs. p. 1-6 6 p.

    Research output: Contribution to journalArticlepeer-review

    3 Scopus citations
If you made any changes in Pure these will be visible here soon.